Commentary Few would argue the United States, or any country for that matter, was prepared for the COVID-19 pandemic, even though, starting in 2003, the U.S. devoted $5.6 billion to fund Project Bioshield, running through 2013, and another $2.8 billion of funding through 2018. Project Bioshield was designed to prepare the United States against a bio attack, including provisions for the stockpiling and distribution of vaccines. Though Covid-19 was a new virus, congressional testimony from 2003 paints a concerning picture about what we knew—and when—about the family of viruses from which it originated. “I am particularly interested in learning how Project BioShield would assist in addressing the current public health emergency created by the epidemic known as Severe Acute Respiratory Syndrome [SARS],” said Tom Davis, chairman of the Committee on Government Reform. “More than 2,000 suspected cases of this mysterious disease have been reported in 17 nations, including the United States, with …